{
    "2020-11-06": [
        [
            {
                "time": "2020-10-31",
                "original_text": "【华创证券】大参林（603233）2020年三季报点评：省外拓展稳步推进，单三季度业绩超预期",
                "features": {
                    "keywords": [
                        "大参林",
                        "三季报",
                        "省外拓展",
                        "业绩超预期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-10-31",
                "original_text": "【公司点评】大参林 (603233)丨三季报点评：业绩持续高增长，并购发力河南市场",
                "features": {
                    "keywords": [
                        "大参林",
                        "三季报",
                        "业绩高增长",
                        "并购",
                        "河南市场"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-10-31",
                "original_text": "三季报亮眼：业绩增长超三成，大参林后劲十足",
                "features": {
                    "keywords": [
                        "三季报",
                        "业绩增长",
                        "大参林"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-01",
                "original_text": "医药2021年度策略：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "医药",
                        "年度策略"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-01",
                "original_text": "医药行业2021年投资策略：“双循环”背景下 “创新升级＋进口替代”引领医药大时代",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资策略",
                        "双循环",
                        "创新升级",
                        "进口替代"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}